Presentation and outcome of patients with systemic amyloidosis undergoing dialysis

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 2, 2008, Pages 375-381

  Bollée, Guillaume ^a   Guery, Bruno ^a   Joly, Dominique ^a   Snanoudj, Renaud ^b   Terrier, Benjamin ^a   Allouache, Mahmoud ^c   Mercadal, Lucile ^c   Peraldi, Marie Noëlle ^d   Viron, Béatrice ^e   Fumeron, Christine ^f   Elie, Caroline ^a   Fakhouri, Fadi ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b BICÊTRE HOSPITAL   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e AURA   (France)

^f Ctr d'Hemodialyse Henri Kuntziger   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOIDOSIS; ARTICLE; FEMALE; HUMAN; MALE; MIDDLE AGED; MORTALITY; PROGNOSIS; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

AMYLOIDOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 42549145388     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02470607     Document Type: Article

References (20)

1. Dember L: Amyloidosis associated Kidney Disease. J Am Soc Nephrol 17: 3458-3471, 2006
2. Gertz MA, Kyle RA, O'Fallon WM: Dialysis support of patients with primary systemic amyloidosis: A study of 211 patients. Arch Intern Med 11: 2245-2250, 1992
3. Moroni G, Banfi G, Montoli A, Bucci A, Bertani T, Ravelli M, Pozzi C, Leonelli M, Lupo A, Volpi A, et al Clin Nephrol 2: 81-85, 1992
4. Martinez-Vea A, Garcia C, Carreras M, Revert L, Oliver JA: End-stage renal disease in systemic amyloidosis: Clinical course and outcome on dialysis. Am J Nephrol 4: 283-289, 1990
5. Sanai T, Nanishi F, Nagata M, Hirano T, Suematsu E, Esaki Y, Miyahara H, Iida M: Role of amyloidosis in determining the prognosis of dialyzed patients with rheumatoid arthritis. Rheumatol Int 4: 363-367, 2007
6. Kuroda T, Tanabe N, Sato H, Ajiro J, Wada Y, Murakami S, Hasegawa H, Sakatsume M, Nakano M, Gejyo F: Outcome of patients with reactive amyloidosis associated with rheumatoid arthritis in dialysis treatment. Rheumatol Int 12: 1147-1153, 2006
7. Gertz MA Kyle RA: Secondary systemic amyloidosis: Response and survival in 64 patients. Medicine (Baltimore) 4: 246-256
8. Ylinen K, Gronhagen-Riska C, Honkanen E, Ekstrand A, Metsärinne K, Kuhlbäck B: Outcome of patients with secondary amyloidosis in dialysis treatment. Nephrol Dial Transplant 7: 908-912, 1992
9. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G: Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 4: 319 -328, 2005
10. Durie B, Salmon SE: A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36: 842-854, 1975
11. Palladini G, Perfetti V, Perlini S, Obici L, Lavatelli F, Caccialanza R, Invernizzi R, Comotti B, Merlini G: The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 105: 2949-2951, 2005
12. Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, Anderson JJ, O'Hara C, Finn KT, Libbey CA, Wiesman J, Quillen K, Swan N, Wright DG: High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An 8-year study. Ann Intern Med 140: 85-93, 2004
13. Vesole DH, Perez WS, Akasheh M, Boudreau C, Reece DE, Bredeson CN; Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant Research: High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study. Mayo Clin Proc 81: 880-888, 2006
14. Sakhuja V, Jha V, Varma S, Joshi K, Gupta KL, Sud K, Kohli HS: Renal involvement in multiple myeloma: A 10 year study. Ren Fail 22: 465-477, 2000
15. Knudsen LM, Hjorth M, Hippe E: Renal failure in multiple myeloma: Reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 65: 175-181, 2000
16. Sharland A, Snowdon L, Joshua DE, Gibson J, Tiller DJ: Hemodialysis: An appropriate therapy in myeloma-induced renal failure. Am J Kidney Dis 30: 786-792, 1997
17. Shah KB, Inoue Y, Mehra MR: Amyloidosis and the heart: A comprehensive review. Arch Intern Med 17: 1805-1813, 2006
18. Dubrey SW, Cha K, Anderson J, Chamarthi B, Reisinger J, Skinner M, Falk RH: The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 91:141-157.1998
19. Iliou MC, Fumeron C, Benoit MO, Tuppin P, Calonge VM, Moatti N, Buisson C, Jacquot C: Prognostic value of cardiac markers in ESRD: Chronic Hemodialysis and New Cardiac Markers Evaluation (CHANCE) study. Am J Kidney Dis 42: 513-523, 2003
20. Dispenzieri A, Kyle RA, Gertz MA, Therneau TM, Miller WL, Chandrasekaran K, McConnell JP, Burritt MF, Jaffe AS: Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 361: 1787-1789, 2003